Home > News > featured news > Mathematical Method Provides Deeper Understanding of Drug Interactions

Mathematical Method Provides Deeper Understanding of Drug Interactions

Technology Networks | November 13, 2019

Researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences have developed a new methodology characterizing more precisely how drugs influence each other when combined during treatment. Their analysis of over 30k drug pairs applied to cell lines identified 1,832 interactions between 242 different drugs and sheds new light on how drugs perturb the underlying molecular networks. Combining two or more drugs can be an effective treatment of diverse diseases, such as cancer. Yet, at the same time, the wrong drug combination can cause major side effects. Currently there is no systematic understanding of how different drugs influence each other. Thus, elucidating how two given drugs interact, and whether they have a beneficial effect, would mean a major step towards drug development to treat diseases more effectively in the future. On a molecular level, drugs cause complex perturbations of various cellular processes in our body. These processes are orchestrated by an intricate network of molecular interactions, the so-called interactome. Over the last decade, numerous studies have revealed a close relationship between the structure of the interactome and the functional organization of the molecular machinery within the cell. This opened exciting opportunities for using network-based approaches to investigate the foundations of both healthy and disease states. Following this trend, Principal Investigator Jörg Menche and his group at CeMM developed a novel mathematical framework for mapping out precisely how different perturbations of the interactome influence each other.

More featured news

Spotlight

Pharmaceutical marketing: ethical and responsible conduct

At EY, we have conducted a survey among healthcare professionals (HCPs) and pharmaceutical companies to understand their perspective of the Medical Council of India’s (MCI) guidelines and the Department of Pharmaceuticals’ (DoP) marketing code. We are pleased to share the findings of our study with you in this report.

Related News

PHARMA TECH

Pfizer, BioNTech COVID-19 vaccine works in more contagious coronavirus variants

Pfizer | January 11, 2021

Newly emerged variants of the novel coronavirus have sparked a key question: Will existing COVID-19 vaccines be less effective against them? But scientists have preliminary data showing that may not be the case, at least for Pfizer and BioNTech’s shot. Researchers from the University of Texas and Pfizer found that, in lab dishes, the vaccine was able to neutralize an engineered version of a variant, which bears an N501Y mutation in its spike protein. The finding was published in bioRxiv and hasn’t been peer-reviewed. Variants of coronavirus with this mutation were first discovered in the U.K. and South Africa and immediately grabbed global attention because they are more contagious. Currently available COVID vaccines—including Pfizer and BioNTech’s Comirnaty, or BNT162b2—target the spike protein of SARS-CoV-2, the coronavirus behind COVID-19. The N501Y mutation improves the ability of the virus’ spike protein to bind to its receptor on human cells, making it easier to gain entry for infection. To test whether Comirnaty worked against the mutation, the scientists collected antibodies from 20 vaccinated trial participants and compared their ability to kill off the engineered virus with the N501Y mutation to their ability to neutralize the strain on which Pfizer and BioNTech based Comirnaty.

Top U.S. health officials self-quarantine after COVID-19 cases in White House

Fiercepharma | May 11, 2020

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. As many businesses in America take steps toward carefully reopening, top U.S. officials guiding the pandemic response are dealing with a COVID-19 outbreak in the country's most high-profile workplace—the White House. After a White House staffer tested positive for COVID-19, FDA Commissioner Stephen Hahn, M.D.; National Institute of Allergy and Infectious Diseases Director Anthony Fauci, M.D.; and Centers for Disease Control and Prevention Director Robert Redfield, M.D., are going into partial or full quarantines for two weeks, CNN reports.

US pharmaceutical supply chain unprepared for COVID-19

Healio | April 27, 2020

In this guest editorial, Pinar Keskinocak, PhD, director of the Center for Health and Humanitarian Systems and a professor in the H. Milton Stewart School of Industrial and Systems Engineering at Georgia Institute of Technology, and Evren Ozkaya, PhD, founder and CEO of the management consulting and digital solutions firm Supply Chain Wizard, discuss how pandemics create chaos in global medical supply chains and ways to alleviate this burden. Pandemics encumber the supply of medications needed to fight them and also the supply of other critical pharmaceuticals with potentially grave consequences for public health. Pandemics do this by disrupting global supply chains in general, and pharmaceutical supply chains are particularly vulnerable. America’s medical supply chain is not prepared for this. But government and industry can help it cope if they react rapidly.